SLC5A2 and hydrops fetalis: As a result, these models could enable prospective identification of individuals at increased risk for HF (and HF subtypes) for targeted screening (e.g., biomarkers, echocardiography), prevention strategies (e.g., sodium glucose co‐transporter 2 inhibitors [SGLT2i]), and recruitment of high‐risk phenotypes for randomized clinical trials focused on HF prevention.